Athenex

$13.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.23 (+1.68%) Today
$0.00 (0.00%) As of 12:10 PM UTC after-hours

Why Robinhood?

You can buy or sell Athenex and other stocks, options, and ETFs commission-free!

About ATNX

Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. The listed name for ATNX is Athenex, Inc. Common Stock.

CEO
Yiu Nam Lau
Employees
574
Headquarters
Buffalo, New York
Founded
2003
Market Cap
1.30B
Price-Earnings Ratio
Dividend Yield
Average Volume
576.67K
High Today
$13.99
Low Today
$13.72
Open Price
$13.74
Volume
211.33K
52 Week High
$18.35
52 Week Low
$5.63

Collections

ATNX Earnings

-$0.53
-$0.35
-$0.18
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like